Chronic Lymphocytic Leukemia

Richard R. Furman, MD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.

The FDA has approved acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Anthony R. Mato, MD, MSCE, discusses ibrutinib-based combinations in chronic lymphocytic leukemia.

Jonathon B. Cohen, MD, MS, discusses fixed-duration therapy in chronic lymphocytic leukemia.

Jonathon B. Cohen, MD, MS, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.

A supplemental new drug application has been submitted to the FDA for ibrutinib (Imbruvica) for use in combination with rituximab (Rituxan) for the first-line treatment of patients ≤70 years old with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Othman Al-Sawaf, MD, discusses checking complex karyotype in patients with chronic lymphocytic leukemia.

Richard R. Furman, MD, discusses the role of prognostic markers in high-risk chronic lymphocytic leukemia.

Michael J. Keating, MBBS, has devoted much of his career to finding means of controlling chronic lymphocytic leukemia.

Mitchell R. Smith, MD, PhD, division director, Cancer and Blood Disorders, and professor of medicine, GW Cancer Center, discusses the use of PI3K inhibitors in chronic lymphocytic leukemia (CLL).

William G. Wierda, MD, PhD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.

The combination of ublituximab and ibrutinib improved progression-free survival, as determined by an Independent Review Committee, compared with ibrutinib alone in patients with relapsed/refractory high-risk chronic lymphocytic leukemia.

William G. Wierda, MD, PhD, discusses the evolving treatment paradigm in chronic lymphocytic leukemia and ongoing trials looking at novel approaches.

Mitchell R. Smith, MD, PhD, discusses frontline treatment considerations in patients with chronic lymphocytic leukemia.

Tanya Siddiqi, MD, discusses the rationale for the phase I/II TRANSCEND CLL 004 trial investigating the use of the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Anthony R. Mato, MD, MSCE, discusses the current immunotherapy options for patients with chronic lymphocytic leukemia.

William G. Wierda, MD, PhD, discusses the use of CD19-targeted CAR T-cell therapy in the treatment of patients with chronic lymphocytic leukemia.

Rituximab is used ubiquitously in the treatment of B-cell lymphomas, and has set the paradigm the field has been trying to match in drug development.

Mitchell R. Smith, MD, PhD, discusses the use of venetoclax versus ibrutinib in patients with chronic lymphocytic leukemia.

James N. Gerson, MD, discusses the emergence of targeted therapy in chronic lymphocytic leukemia.

Anthony R. Mato, MD, MSCE, discusses where CAR T cell-therapy will fit into the treatment paradigm of chronic lymphocytic leukemia.

James N. Gerson, MD, discusses exciting updates in mantle cell lymphoma and chronic lymphocytic leukemia and other potentially practice-changing trials on the horizon.

Arantxa Romero-Toledo, PhD student, at the Centre for Haemato-Oncology, Barts Cancer Institute, discusses the impact of BTK inhibition on monocytic myeloid-derived suppressor cells (MDSCs) in chronic lymphocytic leukemia (CLL).

Mitchell R. Smith, MD, PhD, discusses the use of chemotherapy versus targeted therapy in patients with newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.

Herbert A. Eradat, MD, associate professor, University of California, Los Angeles Medical Center, discusses data with acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).